Spots Global Cancer Trial Database for alectinib
Every month we try and update this database with for alectinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | NCT01871805 | Non-Small Cell ... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib | NCT02604342 | Non-small Cell ... | Alectinib Docetaxel Pemetrexed | 18 Years - | Hoffmann-La Roche | |
| An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib | NCT04764188 | NSCLC | Alectinib | 18 Years - | Hoffmann-La Roche | |
| A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer | NCT03155009 | Carcinoma, Non-... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | NCT03202940 | Non-small Cell ... | Alectinib Cobimetinib | 18 Years - | Massachusetts General Hospital | |
| A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | NCT04302025 | Non-small Cell ... | Alectinib Entrectinib Vemurafenib (En... Cobimetinib (En... Pralsetinib (En... Atezolizumab SBRT Resection Chemotherapy Divarasib | 18 Years - | Genentech, Inc. | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients | NCT04979988 | ALK-positive No... | Lortlatinib | 20 Years - | Pfizer | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | NCT03737994 | Lung Non-Squamo... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alectinib Brigatinib Carboplatin Ceritinib Cisplatin Crizotinib Ensartinib Lorlatinib Pemetrexed | 18 Years - | National Cancer Institute (NCI) | |
| Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels | NCT05525338 | Drug Monitoring Carcinoma, Non-... Lung Cancer Anaplastic Lymp... Anaplastic Lymp... | Alectinib | 18 Years - | University Medical Center Groningen | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | NCT02450903 | Non-Small-Cell ... | LDK378 | 18 Years - | Novartis | |
| Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy | NCT02271139 | Non-Small Cell ... | Alectinib | 18 Years - | Genentech, Inc. | |
| Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC | NCT04997382 | Non-small Cell ... | Chemotherapy al... Chemotherapy al... | 18 Years - 75 Years | Hunan Province Tumor Hospital | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | NCT03202940 | Non-small Cell ... | Alectinib Cobimetinib | 18 Years - | Massachusetts General Hospital | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer | NCT03596866 | ALK+ Advanced N... | Brigatinib Alectinib | 18 Years - | Takeda | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | NCT05725200 | Metastatic Colo... | Alectinib Cetuximab Crizotinib Dasatinib Everolimus Encorafenib Gemcitabine Idelalisib Larotrectinib Methotrexate Palbociclib Panobinostat Pembrolizumab Petrozumab Trastuzumab Talazoparib Venetoclax | 18 Years - | Oslo University Hospital | |
| Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea | NCT03271554 | Non-Small Cell ... | Alectinib | 19 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | NCT04774718 | ALK Fusion-posi... | Alectinib | - 17 Years | Hoffmann-La Roche | |
| A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | NCT04302025 | Non-small Cell ... | Alectinib Entrectinib Vemurafenib (En... Cobimetinib (En... Pralsetinib (En... Atezolizumab SBRT Resection Chemotherapy Divarasib | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT02838420 | Anaplastic Lymp... | Alectinib Crizotinib | 18 Years - | Hoffmann-La Roche | |
| Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels | NCT05525338 | Drug Monitoring Carcinoma, Non-... Lung Cancer Anaplastic Lymp... Anaplastic Lymp... | Alectinib | 18 Years - | University Medical Center Groningen | |
| A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants | NCT02075840 | Non-Small Cell ... | Alectinib Crizotinib | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT05170204 | Non-Small Cell ... | Alectinib Entrectinib Durvalumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT05170204 | Non-Small Cell ... | Alectinib Entrectinib Durvalumab | 18 Years - | Hoffmann-La Roche | |
| Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels | NCT05525338 | Drug Monitoring Carcinoma, Non-... Lung Cancer Anaplastic Lymp... Anaplastic Lymp... | Alectinib | 18 Years - | University Medical Center Groningen | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | NCT05987644 | Lung Cancer NSCLC Brain Metastase... | Alectinib Stereotactic Ra... | 18 Years - | Hoosier Cancer Research Network | |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | NCT05987644 | Lung Cancer NSCLC Brain Metastase... | Alectinib Stereotactic Ra... | 18 Years - | Hoosier Cancer Research Network | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| Alectinib Pharmacokinetic in Patients With NSCLC | NCT05713006 | Non-small Cell ... ALK Gene Mutati... | Alectinib Oral ... | 18 Years - | Instituto Nacional de Cancerologia de Mexico | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | NCT04341181 | Cancer Tumors Neoplasms Neoplasia | Alectinib Atezolizumab Avelumab Axitinib Erlotinib Vemurafenib plu... Trastuzumab plu... Trastuzumab emt... Vismodegib Niraparib | 18 Years - | Rigshospitalet, Denmark | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | NCT02091141 | Neoplasms Solid Tumors Biliary Cancer Salivary Cancer Bladder Cancer | Trastuzumab Pertuzumab Erlotinib Vemurafenib Cobimetinib Vismodegib Alectinib Atezolizumab | 18 Years - | Genentech, Inc. | |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | NCT04341181 | Cancer Tumors Neoplasms Neoplasia | Alectinib Atezolizumab Avelumab Axitinib Erlotinib Vemurafenib plu... Trastuzumab plu... Trastuzumab emt... Vismodegib Niraparib | 18 Years - | Rigshospitalet, Denmark | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | NCT05159245 | Advanced Cancer Solid Tumor Haematological ... | Alectinib Cobimetinib Vismodegib Trastuzumab+Per... Entrectinib Atezolizumab Vemurafenib Regorafenib Apalutamide Abemaciclib Selpercatinib Dabrafenib Trametinib Dabrafenib+Tram... Pralsetinib | 18 Years - 100 Years | Helsinki University Central Hospital | |
| NCT Neuro Master Match - N²M² (NOA-20) | NCT03158389 | Glioblastoma, A... | APG101 Alectinib Idasanutlin Atezolizumab Vismodegib Temsirolimus Palbociclib | 18 Years - | University Hospital Heidelberg | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants | NCT02075840 | Non-Small Cell ... | Alectinib Crizotinib | 18 Years - | Hoffmann-La Roche | |
| SMMART Adaptive Clinical Treatment (ACT) Trial | NCT05238831 | Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre... | Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib | 18 Years - | OHSU Knight Cancer Institute | |
| Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | NCT02521051 | Non-Small Cell ... | Alectinib Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | NCT03131206 | ALK-positive No... RET-positive No... RET-positive Th... | Alectinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | NCT03131206 | ALK-positive No... RET-positive No... RET-positive Th... | Alectinib | 18 Years - | Dana-Farber Cancer Institute | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | NCT02013219 | Non-Small Cell ... | Alectinib Atezolizumab Erlotinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | NCT01801111 | Non-Small-Cell ... | Erlotinib Alectinib | 18 Years - | Hoffmann-La Roche | |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer | NCT03445000 | Non-small Cell ... Non-small Cell ... Non-small Cell ... | Alectinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | NCT03194893 | Neoplasms | Alectinib Crizotinib | - | Hoffmann-La Roche | |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| CRAFT: The NCT-PMO-1602 Phase II Trial | NCT04551521 | Metastatic or L... | Vemurafenib Cobimetinib Atezolizumab Trastuzumab Pertuzumab Alectinib Ipatasertib Atezolizumab Atezolizumab Atezolizumab Inavolisib | 18 Years - | German Cancer Research Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
